Myomo Turns a Corner: Reimbursement Wins and a Recurring-Referral Engine
A $35M micro-cap orthotics maker swaps advertising for payer contracts and rehab-center referrals, and the market starts to believe.
MYO · Earnings Call · 2026-05-07
A Micro-Cap Orthotics Maker in the Middle of a Demand-Side Pivot
Myomo (MYO) is a $35 million micro-cap specializing in powered arm orthoses. It reported Q1 2026 on May 7, and while revenue was only up 3% YoY to $10.1M, the composition of that revenue changed profoundly. The stock has surged ~150% in the past 90 days to ~$1.86, and after a -99% drawdown from its 2017 peak, this is a meaningful re-rating. The topline is still modest, but the operating picture is improving: gross margin reached 68.2% (up 100bps), OpEx fell 1% YoY, and adjusted EBITDA narrowed by 20%.From Direct Marketing to Recurring Patient Sources
Historically, Myomo generated demand through expensive direct-to-patient ads. Now it is pivoting to recurring sources: rehab hospitals, O&P providers, and international partners. Recurring referrals now represent 49% of revenue, up from 25% a year earlier. As Paul Gudonis put it: “We are transitioning our go-to-market strategy with a distribution system based on recurring patient sources from rehab hospitals and O&P providers to reduce our customer acquisition costs.” — Paul R. Gudonis, Chief Executive Officer · 2026-05-07 The MyoConnect program has already signed 150 rehab facilities, and the U.S. O&P channel grew 79% YoY. The company is certifying Autobock as Centers of Excellence. In the prior quarter, the company was still describing this as an emerging initiative: “One of our big initiatives this year, is to build this orthotics and prosthetics channel.” — Paul Gudonis, Chief Executive Officer · 2025-05-07 Just a quarter ago, the O&P book was about $900K and roughly 30 units, a small base that is now scaling fast (Dave Henry: “It was about $900,000, and I must say it was roughly 30 units...” — Dave Henry, Chief Financial Officer · 2025-11-10). The shift is visible in the metrics: direct billing fell to 71% of revenue from 79% a year ago, while recurring sources jumped to 49% from 25%. Patient acquisition cost is structurally declining as referrals replace ads.The Payer Contract Breakthrough
The more consequential change is on reimbursement. The Elevance national arrangement, covering Anthem Blue Cross Blue Shield plans in 27 states, has expanded covered lives from 9 million to 158 million in a little over a year. National arrangement is new territory for the company. In the Q&A, Dave Henry confirmed: “where we have contracts with these various plans we have a much higher authorization rate right up front...” — David A. Henry, Chief Financial Officer · 2026-05-07 Higher authorization rates mean fewer appeals and greater predictability. The company also continues to win ALJ hearings for denied claims, but contracts reduce the need for that.Financial Traction and the Path to Profitability
Average selling price hit $58,800, up 9% YoY, driven by CMS fee updates, Medicare Advantage reimbursement, and favorable channel mix. 172 units were delivered in the quarter. Gross margin expanded 100bps to 68.2%. But the sustainability question is real: Dave Henry warned “I do expect that the ASP will come down a bit through the channel mix in the second quarter” — David A. Henry, Chief Financial Officer · 2026-05-07, guiding to a longer-term ~$55,000 ASP. Operating loss narrowed to $3.2M and adjusted EBITDA improved to -$2.3M from -$2.8M. Guidance for Q2 revenue of $10.3-10.8M (up 7-12% YoY) and full-year $43-46M implies a meaningful H2 ramp. Operating loss has improved each of the last two quarters, and management's re-targeted OpEx growth (half the revenue growth) suggests operating leverage is finally kicking in. Beyond the numbers, the company is investing in a randomized controlled trial with the University of Utah to further solidify reimbursement, launching a mobile app that cuts material costs ~10%, and developing the next-generation MyoPro 3. Germany remains a bright spot, with Q1 international revenue at a record ~$2M.This is not a new product story; it's a new go-to-market story. Myomo is trading advertising dollars for referral relationships and payer contracts, and the stock's recent spike suggests the market is starting to price that in.When you add in spinal cord injury, traumatic brain injury and brachial plexus injuries, the addressable U.S. population reaches into the millions, and globally millions more.